Loading...

Surrozen, Inc.

SRZNWNASDAQ
Healthcare
Biotechnology
$0.03
$0.007(35.64%)
U.S. Market opens in 5h 2m

Surrozen, Inc. Fundamental Analysis

Surrozen, Inc. (SRZNW) shows weak financial fundamentals with a PE ratio of -1.03, profit margin of -69.61%, and ROE of 6.11%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position46801.38%
PEG Ratio0.01
Current Ratio9.22

Areas of Concern

ROE6.11%
Operating Margin-12.11%
We analyze SRZNW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -5190.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-5190.2/100

We analyze SRZNW's fundamental strength across five key dimensions:

Efficiency Score

Weak

SRZNW struggles to generate sufficient returns from assets.

ROA > 10%
-2.45%

Valuation Score

Excellent

SRZNW trades at attractive valuation levels.

PE < 25
-1.03
PEG Ratio < 2
0.01

Growth Score

Weak

SRZNW faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
-1.59%

Financial Health Score

Excellent

SRZNW maintains a strong and stable balance sheet.

Debt/Equity < 1
-0.04
Current Ratio > 1
9.22

Profitability Score

Weak

SRZNW struggles to sustain strong margins.

ROE > 15%
6.11%
Net Margin ≥ 15%
-69.61%
Positive Free Cash Flow
No

Key Financial Metrics

Is SRZNW Expensive or Cheap?

P/E Ratio

SRZNW trades at -1.03 times earnings. This suggests potential undervaluation.

-1.03

PEG Ratio

When adjusting for growth, SRZNW's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values Surrozen, Inc. at -1.33 times its book value. This may indicate undervaluation.

-1.33

EV/EBITDA

Enterprise value stands at -3.25 times EBITDA. This is generally considered low.

-3.25

How Well Does SRZNW Make Money?

Net Profit Margin

For every $100 in sales, Surrozen, Inc. keeps $-69.61 as profit after all expenses.

-69.61%

Operating Margin

Core operations generate -12.11 in profit for every $100 in revenue, before interest and taxes.

-12.11%

ROE

Management delivers $6.11 in profit for every $100 of shareholder equity.

6.11%

ROA

Surrozen, Inc. generates $-2.45 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.45%

Following the Money - Real Cash Generation

Operating Cash Flow

Surrozen, Inc. generates limited operating cash flow of $-30.24M, signaling weaker underlying cash strength.

$-30.24M

Free Cash Flow

Surrozen, Inc. generates weak or negative free cash flow of $-30.37M, restricting financial flexibility.

$-30.37M

FCF Per Share

Each share generates $-4.06 in free cash annually.

$-4.06

FCF Yield

SRZNW converts -12.06% of its market value into free cash.

-12.06%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.03

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

-1.33

vs 25 benchmark

P/S Ratio

Price to sales ratio

71.97

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.04

vs 25 benchmark

Current Ratio

Current assets to current liabilities

9.22

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

6.11

vs 25 benchmark

ROA

Return on assets percentage

-2.45

vs 25 benchmark

ROCE

Return on capital employed

-0.47

vs 25 benchmark

How SRZNW Stacks Against Its Sector Peers

MetricSRZNW ValueSector AveragePerformance
P/E Ratio-1.0329.29 Better (Cheaper)
ROE610.83%690.00% Neutral
Net Margin-6960.77%-45102.00% (disorted) Weak
Debt/Equity-0.040.43 Strong (Low Leverage)
Current Ratio9.224.48 Strong Liquidity
ROA-245.15%-14932.00% (disorted) Weak

SRZNW outperforms its industry in 3 out of 6 key metrics, but lagging in Net Margin.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Surrozen, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

65.01%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

88.77%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ